Revolution's pancreatic cancer drug doubles survival, boosts quality of life

• Daraxonrasib halted or reversed tumor progression in nearly 33% of patients versus just 10% with chemotherapy, with 31.6% seeing tumors shrink or disappear compared to 11.2% on chemotherapy
• Side effects were largely manageable: 86.3% experienced rash but only 1.2% discontinued treatment due to adverse events, compared to 11.2% discontinuation in the chemotherapy arm
• The drug is first in a new class called RAS(ON) inhibitors targeting RAS gene mutations; Revolution is already testing it in earlier-stage disease and combination therapies to extend benefits

Revolution Medicine's Pancreatic Cancer Drug Shows Breakthrough Results

Revolution Medicine's experimental pancreatic cancer pill, daraxonrasib, demonstrated groundbreaking efficacy in a 500-patient trial, doubling survival time and establishing a new treatment benchmark for this deadly disease.

Key Trial Results

The phase 3 study tested daraxonrasib against standard chemotherapy in patients who had failed one prior chemotherapy round. The drug reduced the overall risk of death by 60% and extended median survival to 13.2 months versus 6.7 months for chemotherapy patients. Additionally, 31.6% of patients experienced tumor shrinkage or disappearance compared to just 11.2% in the chemotherapy arm. The drug halted or reversed tumor progression by nearly a third overall versus 10% with chemotherapy.

Clinical Significance

Daraxonrasib is the first in a new class of RAS(ON) inhibitors targeting RAS gene mutations present in up to 90% of pancreatic cancers, making it relevant for most patients. In patients with the G12 mutation specifically, tumors remained under control for a median of 7.3 months versus 3.5 months with chemotherapy.

Safety Profile

While 86.3% of patients experienced rash, side effects were largely manageable with antibiotics and topical steroids. Only 1.2% of patients discontinued treatment due to adverse events, compared to 11.2% in the chemotherapy group. Severe side effects occurred in 43.6% of daraxonrasib patients versus 57.5% with chemotherapy.

Market Context

Pancreatic cancer has the highest mortality rate among major cancers. The American Cancer Society estimates 68,000 Americans will be diagnosed this year, with roughly 53,000 deaths. The FDA has granted the drug priority review. Revolution Medicine is already testing daraxonrasib in earlier-stage disease and combination therapies.